Table 3.
Comparison of the clinicopathological manifestations between IgAN-NS and IgAN-NR without CR.
| IgAN-NR | IgAN-NS | p | |
|---|---|---|---|
| N | 62 | 57 | |
| Age, y | 42.50 [36.00, 50.50] | 40.00 [27.00, 52.00] | .3 |
| Male | 35 (56.5) | 26 (45.6) | .3 |
| Follow-up duration, m | 40.85 (33.78) | 42.05 (35.47) | .9 |
| eGFR | 57.34 (26.50) | 52.49 (33.34) | .4 |
| Body mass index | 31.52 (40.45) | 24.38 (3.80) | .2 |
| Systolic blood pressure, mmHg | 130.78 (12.39) | 131.27 (14.54) | .8 |
| Diastolic blood pressure, mmHg | 81.81 (8.18) | 79.95 (8.34) | .2 |
| Mean arterial pressure, mmHg | 125.41 (11.28) | 123.71 (11.94) | .4 |
| Hemoglobin, g/L | 125.91 (22.33) | 110.05 (24.95) | <.001 |
| Serum creatinine, mg/dL | 1.90 (1.77) | 2.49 (3.04) | .1 |
| Serum albumin, g/L | 35.98 (4.57) | 25.32 (3.50) | <.001 |
| Total cholesterol, mmol/L | 5.63 (1.34) | 6.69 (2.17) | .002 |
| Triglyceride, mmol/L | 3.01 (1.91) | 2.33 (1.43) | .03 |
| HDL-cholesterol, mmol/L | 1.03 (0.28) | 1.15 (0.51) | .1 |
| LDL-cholesterol, mmol/L | 3.05 (0.99) | 3.92 (1.47) | <.001 |
| Uric acid, mmol/L | 423.03 (99.63) | 417.89 (135.43) | .8 |
| Fibrinogen, g/L | 4.33 (1.14) | 5.00 (1.45) | .005 |
| C-reactive protein, g/L | 4.03 (5.99) | 10.94 (28.41) | .06 |
| Serum IgA, g/L | 3.56 (1.23) | 3.05 (1.05) | .02 |
| Proteinuria, g/24 h | 5.62 (2.05) | 7.50 (3.31) | <.001 |
| Urine red blood cell count, RBC/μL | 163.10 [27.45, 540.72] | 302.12 [126.75, 515.85] | .04 |
| Urine white blood cell count, RBC/μL | 127.15 [64.91, 232.81] | 205.97 [107.36, 545.53] | .008 |
| Composite endpoint | 21 (33.9) | 28 (49.1) | .1 |
| Therapy | |||
| Renin-angiotensinsystem inhibitor | 54 (87.1) | 44 (77.2) | .2 |
| Steroid | 37 (59.7) | 51 (89.5) | <.001 |
| Immunosuppressant | 27 (43.5) | 29 (50.9) | .5 |
| Oxford classification | |||
| M1 | 14 (38.9) | 26 (72.2) | .009 |
| E1 | 18 (43.9) | 20 (55.6) | .4 |
| S1 | 33 (84.6) | 33 (91.7) | .6 |
| T | .5 | ||
| T1 | 14 (34.1) | 13 (36.1) | |
| T2 | 16 (39.0) | 17 (47.2) | |
| C1 | 41 (66.1) | 34 (59.6) | .6 |
| Immunofluorescence | |||
| IgA | .6 | ||
| + | 26 (41.9) | 23 (40.4) | |
| ++ | 3 (4.8) | 5 (8.8) | |
| +++ | 33 (53.2) | 28 (49.1) | |
| ++++ | 0 (0.0) | 1 (1.8) | |
| IgM | .7 | ||
| + | 20 (32.3) | 20 (35.1) | |
| ++ | 5 (8.1) | 8 (14.0) | |
| +++ | 1 (1.6) | 1 (1.8) | |
| IgG | .6 | ||
| + | 5 (8.1) | 4 (7.0) | |
| ++ | 1 (1.6) | 0 (0.0) | |
| C3 | .4 | ||
| + | 29 (46.8) | 23 (40.4) | |
| ++ | 19 (30.6) | 13 (22.8) | |
| +++ | 9 (14.5) | 15 (26.3) |
Numerical variables are reported as means (SD) or medians [IQR], while categorical variables are presented as counts (%). The composite endpoint was referred to a continuous decline in eGFR of ≥30% from the baseline or reaching ESRD.
IgAN-NS: IgAN with NS; IgAN-NR: IgAN with nephrotic-range proteinuria; E1: endocapillary hypercellularity; M1: mesangial hypercellularity; T1-2: severity of interstitial fibrosis/tubular atrophy; S1: segmental glomerulosclerosis/adhesion; C1: presence of crescent; CR: complete remission of proteinuria; PR:partial remission of proteinuria. a p-value was adjusted for multiple comparison.